How to Cite
Abstract
Objective: to evaluate the diagnostic accuracy of sentinel lymph node biopsy after neoadjuvant chemotherapy. Materials and methods: the study included 264 patients with early (operable) and locally advanced breast cancer (cT1N1-3, cT2N0-3, cT3N0-3, cT4N0-3). All patient underwent corebiopsy with histological examination and ICH (to determine the tumor grade (G), expression of ER, PR, Ki67, Her2), fine needle aspiration of suspicious axillary lymph nodes. Before, during and after the neoadjuvant therapy, all patients undergo: physical examination (palpation), mammography, ultrasound, SPECT-CT. The effect of neoadjuvant chemotherapy was evaluated after the 2nd, 4th, and 6th cycles of therapy. 197 patients (74.6%) had tumors more than 2 cm (cT2), 210 (79.8%) were N + (cN1-N3), 174 patients (65.9%) had luminal tumors (ER+), 84 patients (31.8%) had triple-negative breast cancer (ER-, PR-, HER2-) and 53 patients (20%) had HER2-positive breast cancer. Most patients (56.4%) had a high level (> 30%) of Ki67 expression. Results: 210 of 263 patients (79.8%) had metastases in regional lymph nodes before treatment. Almost half of them had a decrease in the stage from N + to ycN0 after NACT. According to the ultrasound data 48 patients had decreasing of the stage to ycN0. Sentinel lymph node biopsy showed ypN0 category in 35 patients and ypN+ in 13 patients. The false-negative rate was 5.7%. The sensitivity of the method was 94.3%, the accuracy of ultrasound was 95.8%. According to the SPET-CT data 51 patients had decreasing of the stage to ycN0. Sentinel lymph node biopsy showed ypN0 category in 35 patients and ypN+ in 16 patients. The false-negative rate was 2.85%. The sensitivity of SLNB after NACT in patients cN0/cN+ → ycN0 was 91.2%, accuracy - 96.3%, predictive value of the negative result - 92.4%. Conclusion: SLNB can be performed in cN0/cN+ → ycN0 patients after NACT, provided that 3 or more sentinel lymph nodes are removed and there are no tumor cells in them.
References
Криворотько П.В., Дашян Г.А., Палтуев Р.М. и др. Биопсия сигнальных лимфоузлов при раке молочной железы // Злокачественные опухоли. - 2016 - № 4, спецвыпуск 1. - С. - 4-8.
Семиглазов В.В., Криворотько П.В., Семиглазов В.Ф. Международные рекомендации по лечению раннего рака молочной железы / рук. для врачей под ред. В.Ф.Семиглазова. -М.МК, 2020. - 232 с.
Kuehn Т., Bauerfeind I., Fehm Т. et al. Sentinel-lymphnode biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA):a prospective, multicentre cohort study // Lancet Oncol. - 2013. - Vol. 14. - P 609-618.
Boileau J.F., Poirier B., Basik M. et al. Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study // J Clin Oncol. - 2015. - Vol. 33. - P. 258-264.
Boughey J.C., Suman V.J., Mittendorf E.A. et al. Alliance for Clinical Trials in Oncology. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients withnode-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial // JAMA. - 2013. - Vol. 310. - P. 1455-1461.
Eberl M.M. et al. BI-RADS classification for management of abnormal mammograms // J. Am. Board. Fam. Med. - 2006. - Vol. 19. - № 2. - P 161-164.
Канаев С.В. и др. Возможность ОФЭКТ-КТ в диагностике опухолевого поражения подмышечных лимфоузлов у больных раком молочной железы // Вопр. он-кол. - 2014. - Т.60. - № 2. - С. 51-56.
Schulz-Wendtland R. Neoadjuvant chemotherapy-monitoring: clinical examination, ultrasound, mammography, MRI, elastography: only one, only few or all? // Eur. J. Radiol. - 2012. - Vol. 81. - P 147-148.
Fontein D.B., van de Water W., Mieog J.S. et al. Timing of the sentinel lymph node biopsy in breast cancer patients receiving neoadjuvant therapy - recommendations for clinical guidance // Eur J Surg Oncol. - 2013. - Vol. 39. - P. 417-424.
Geng C., Chen X., Pan X., Li J. The feasibility and accuracy of sentinel lymph node biopsy in initially clinically nodenegative breast cancer after neoadjuvant chemotherapy: a systematic review and meta-analysis // PLoS One. - 2016. - Vol. 11. - e0162605.
Schipper R.J., Moossdorff M., Beets-Tan R.G.H. et al. Noninvasive nodal restaging in clinically node positive breast cancer patients after neoadjuvant systemic therapy: a systematic review // Eur J Radiol. - 2015. - Vol. 84. - P 41-47.
Rebollo-Aguirre A.C., Gallego-Peinado M., Menjуn-Beltr6n S. et al. Sentinel lymph node biopsy in patients with operable breast cancer treated with neoadjuvant chemotherapy // Rev EspMed Nucl Imagen Mol. - 2012. - Vol. 31. - P. 117-123.
Schwentner L., Helms G., Nekljudova V. et al. Using ultrasound and palpation for predicting axillary lymph node status following neoadjuvant chemotherapy - results from the multi-center SENTINA trial // Breast. - 2016. - Vol. 31. - P. 202-207.
Hieken T.J., Boughey J.C., Jones K.N. et al. Imaging response and residual metastatic axillary lymph node disease after neoadjuvant chemotherapy for primary breast cancer // Ann Surg Oncol. - 2013. - Vol. 20. - P 3199-3204.
Simons J.N., van Nijnatten T.J.A., van Pol C.C. et al. Diagnostic accuracy of different surgical procedures for axillary stating after neoadjuvant systemic therapy in node-positive breast cancer: systemic review and metaanalysis // Ann Surg. - 2019. - Vol. 269. - P 432442.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2020